Please assess the completion status of the following clinical trial:

Trial Title: Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of localized breast cancer~  * Stage I-IIIA disease~ * Adequately treated breast cancer~    * No clinical or radiological evidence of recurrent or metastatic disease~* Baseline total lumbar spine or femoral neck bone mineral density T-score \< -2.0 standard deviation (e.g., a patient with a T score of -2.1 is eligible)~* Hormone-receptor status:~  * Estrogen receptor and/or progesterone receptor-positive breast cancer~PATIENT CHARACTERISTICS:~* Female~* Postmenopausal, defined by 1 of the following criteria:~  * Age \> 55 years with cessation of menses~ * Age ≤ 55 years with spontaneous cessation of menses for \> 1 year~ * Age ≤ 55 years with spontaneous cessation of menses for ≤ 1 year, but amenorrheic (e.g., spontaneous or secondary to hysterectomy), AND has postmenopausal estradiol levels~ * Bilateral oophorectomy~* ECOG performance status 0-2~* Life expectancy ≥ 5 years~* WBC ≥ 3,000/mm³ OR granulocyte count ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Alkaline phosphatase ≤ 3 times upper limit of normal (ULN)~* AST ≤ 3 times ULN~* Creatinine \< 2.0 mg/dL~* Creatinine clearance ≥ 45 mL/min~* No hypercalcemia (i.e., calcium level \> 1 mg/dL above ULN) OR hypocalcemia (i.e., calcium level \> 0.5 mg/dL below lower limit of normal) within the past 6 months~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* No other nonmalignant systemic diseases, including any of the following:~  * Uncontrolled infection~ * Uncontrolled diabetes mellitus~ * Uncontrolled thyroid dysfunction~ * Disease affecting bone metabolism (hyperparathyroidism, hypercortisolism, Paget's disease, osteogenesis imperfecta)~ * Malabsorption syndrome~* No uncontrolled seizure disorders associated with falls~* No known hypersensitivity to zoledronate or other bisphosphonates, letrozole, calcium, or vitamin D~* No concurrent active dental problems, including any of the following:~  * Infection of the teeth or jawbone (maxillary or mandibular)~ * Dental or fixture trauma~ * Prior or current diagnosis of osteonecrosis of the jaw~ * Exposed bone in the mouth~ * Slow healing after dental procedures~* No contraindication to spine dual energy x-ray absorptiometry (DXA) as defined by any of the following:~  * History of surgery at the lumbosacral spine, with or without implantable devices~ * Scoliosis with a Cobb angle \> 15 degrees at the lumbar spine~ * Immobility, hyperostosis, or sclerotic changes at the lumbar spine, or evidence of sclerotic abdominal aorta sufficient to interfere with DXA scan~ * Disease of the spine that would preclude the proper acquisition of a lumbar spine DXA~* No condition that would preclude study follow-up or compliance~* No psychiatric illness that would preclude giving informed consent~PRIOR CONCURRENT THERAPY:~* More than 3 weeks since prior and no other concurrent oral bisphosphonates~* No prior intravenous bisphosphonates~* No prior aromatase inhibitor therapy~* More than 6 months since prior anabolic steroids or growth hormone~* More than 2 weeks since prior and no concurrent inhibitor of osteoclastic bone resorption (e.g., calcitonin, mithramycin, or gallium nitrate)~* More than 30 days since prior systemic investigational drug and/or device~* More than 7 days since prior topical investigational drug~* More than 6 weeks since prior and no concurrent dental or jaw surgery (e.g., extraction, implants)~* Concurrent short-term corticosteroid therapy allowed~* No concurrent sodium fluoride, parathyroid hormone, or tibolone~* No other concurrent investigational drug or device

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- zoledronic acid (Type: EXPERIMENTAL): 4 mg 15 minutes IV infusion. If creatinine clearance is ≤ 60, dosage should be adjusted as follows:CrCl 50-60: 3.5 mg; CrCl 40-49: 3.3 mg; CrCl 30-39: 3.0 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete